Roche CEO: No Plans to Sell Diabetes Business

The transcript discusses the challenges faced by the industry, particularly in the diabetes care segment. It highlights the company's performance, noting that the diagnostics division has grown by 7% in local currencies, despite a decline in the diabetes care market. The company remains committed to this segment, emphasizing its market leadership and rejecting any plans to sell the unit, even for $5 billion.

What percentage of total sales does the diabetes scale account for?

How did the diagnostics division perform overall?

What was the growth percentage in local currencies?

What challenges is the industry currently facing?

What commitment does the company have regarding the difficult phase?